21000 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Growth hormone [GH] (Somatotropin)
POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#2INJECTABLE NUTRIENT SOLUTION
#3AMNIOTIC FLUID COMPOSITION AND METHOD OF USING
#4BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME
#5PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#6CANCER-KILLING CELLS
#7METHODS FOR IMPROVING MUSCLE MASS, STRENGTH, OR FUNCTION WITH A COMBINATION OF TESTOSTERONE AND GROWTH HORMONE
#8Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
#9METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME
#10VECTORS FOR DELIVERY OF HUMAN GROWTH HORMONE GENE AND MULTIPLE THERAPEUTIC GENES INTO CENTRAL NERVOUS SYSTEM BY CROSSING BLOOD BRAIN BARRIER
#11LIPID DEPOT FORMULATIONS
#12ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE
#13CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#14TOXIN-DERIVED DELIVERY CONSTRUCTS
#15COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION
#16PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF
#17ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#18MICRONEEDLE FORMULATION, MICRONEEDLE PATCH, AND PREPARATION METHODS THEREOF
#19DEVICE, SYSTEM AND METHODS FOR THE ORAL DELIVERY OF THERAPEUTIC COMPOUNDS
#20METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
#21PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDREN
#22GROWTH HORMONE RECEPTOR ANTAGONISTS EXHIBITING INCREASED RECEPTOR BINDING PROPERTIES AND INCREASED SERUM HALF-LIFE
#23METHODS FOR TREATING ALZHEIMERS DISEASE AND RELATED DEMENTIAS AND AGING USING PEGYLATED GROWTH HORMONE RECEPTOR ANTAGONISTS
#24Methods and Apparatus to Separate Biological Entities
#25METHODS AND COMPOSITIONS FOR TREATMENT OF PENILE DEFECTS
#26PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDREN
#27Novel Polymeric hGH Prodrugs
#28SWALLOWABLE DRUG DELIVERY DEVICE AND METHODS OF DRUG DELIVERY
#29Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#30Neuronal diencephalon stem cells and exosomes thereof for the treatment and prevention of diseases
#31COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION
#32COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION
#33ORAL ALGAL OIL BASED GASTRO-INTESTINAL TRACT PERMEABLE PEPTIDE COMPOSITION
#34Long-Acting Growth Hormone Treatment
#35COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION
#36COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION
#37COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION
#38TOXIN-DERIVED DELIVERY CONSTRUCTS
#39PHARMACEUTICALS AND DOSING MEANS FOR HUMAN AGING REVERSAL
#40COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION
#41SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#42METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#43CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#44CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#45Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#46CANCER-KILLING CELLS
#47INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
#48CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#49POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#50ORAL POLYPEPTIDE FORMULATIONS
#51Device, system and methods for the oral delivery of therapeutic compounds
#52GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION COMBINATION THERAPY
#53PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDREN
#54COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC PAIN
#55ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#56THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#57ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE
#58METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
#59CONJUGATE OF FUNCTIONAL POLYPEPTIDE VARIANT, AND USE THEREOF
#60CANCER-KILLING CELLS
#61METHOD FOR TREATMENT OF TYPE-1 DIABETES IN A SUBJECT IN NEED THEREOF
#62Combination Therapy with Controlled-Release CNP Agonists
#63BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME
#64EFFECTS OF CELL-FREE FAT LIQUID EXTRACT ON MACROPHAGE POLARIZATION MODULATION AND DISEASE TREATMENT
#65COMPOSITIONS FOR TREATING RESPIRATORY TRACT INFECTION AND USES THEREOF
#66MIC-1 compounds and use thereof
#67ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#68Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
#69TOXIN-DERIVED DELIVERY CONSTRUCTS
#70POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS
#71Stimulation of Human Meibomian Gland Function
#72STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#73LIPID DEPOT FORMULATIONS
#74METHOD OF TREATING CANCER AND METHOD OF SENSITIZING CANCER CELLS TO THE ACTION OF CHEMOTHERAPEUTIC AGENTS VIA GROWTH HORMONE RECEPTOR ANTAGONISTS OR KNOCK DOWN
#75BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME
#76AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING FUSION PROTEIN OF SERUM ALBUMIN AND GROWTH HORMONE
#77Pharmaceutical compositions and related methods of delivery
#78Pharmaceutical compositions and related methods of delivery
#79REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES
#80ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#81FACTOR IX GENE THERAPY
#82Swallowable drug delivery device and methods of drug delivery
#83Long-Acting Therapeutic Fusion Proteins
#84Long-acting polypeptides and methods of producing and administering same
#85AN AMNIOTIC FLUID COMPOSITION AND METHOD OF USING
#86CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#87CONJUGATE OF BIO-RELATED SUBSTANCE AND BLOCK POLYMER, AND BLOCK POLYMER DERIVATIVE FOR OBTAINING SAID CONJUGATE
#88THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#89Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
#90Microfluidic Chip for Acoustic Separation of Biological Objects
#91mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
#92Salts of potassium ATP channel openers and uses thereof
#93Growth hormone antagonist and anti-cancer composition combination therapy
#94Use of macimorelin in assessing growth hormone deficiency in children
#95DRUG CONJUGATE PREPARED USING ALDEHYDE GROUP AT END OF HYALURONIC ACID
#96METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
#97NEUROLOGICAL REHABILITATION AND TRAINING METHOD UTILIZING OCULOMOTOR, VISUAL AND/OR VESTIBULAR REHABILITATION TASKS ON SUBJECTS WITH PHARMACOLOGICALLY INDUCED NEUROPLASTICITY
#98BIODEGRADABLE DRUG DELIVERY COMPOSITION
#99METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
#100Protein-containing aqueous liquid formulation
#101TREATMENTS RELATED TO GH/IGF-1 AXIS INHIBITION
#102Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#103PEGylated recombinant human growth hormone compounds
#104CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#105MIC-1 COMPOUNDS AND USE THEREOF
#106Pharmaceutical Combination Comprising Epidermal Growth Factor and Secretagogue Peptide GHRP6 for the Restoration of Brain Damage
#107Cancer-killing cells
#108Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
#109Polymer compositions for storage and release of polypeptides
#110Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#111Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugate
#112Radiation-Sterilized Biodegradable Drug Delivery Compositions
#113LIPID DEPOT FORMULATIONS
#114COMPOSITIONS FOR TREATMENT OF ANNULAR SPINAL DISC INJURY
#115Toxin-derived delivery constructs for pulmonary delivery
#116Composition and Method for Improving Sensorineural Hearing
#117ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#118Methods and compositions for treatment of penile defects
#119METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#120Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
#121Degradable polyethylene glycol conjugate
#122Applied Artificial Intelligence Technology for Hormone Therapy Treatment
#123LONG-ACTING IGF-1 OR IGF-1 VARIANTS AND METHODS OF PRODUCING SAME
#124METHODS AND COMPOSITIONS FOR TREATMENT OF PENILE DEFECTS
#125Pharmaceutical compositions and related methods of delivery
#126Polymeric hGH prodrugs
#127Therapeutic pegylated growth hormone antagonists
#128Compositions and methods for treatment of cutaneous or muscle incision pain
#129METHOD FOR MANUFACTURING FEED CONTAINING SALMON GROWTH HORMONE, FEED CONTAINING SALMON GROWTH HORMONE, AND LIQUID CONTAINING SALMON GROWTH HORMONE
#130ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE
#131STIMULATION OF HUMAN MEIBOMIAN GLAND FUNCTION
#132Device, system and methods for the oral delivery of therapeutic compounds
#133Combination therapy with controlled-release CNP agonists
#134Dry growth hormone composition transiently linked to a polymer carrier
#135Pharmaceuticals and dosing means for human aging reversal
#136Polymer derivatives having particular atom arrangements
#137Salts of potassium ATP channel openers and uses thereof
#138Swallowable drug delivery device and methods of drug delivery
#139STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#140Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#141Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#142USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF
#143Short duration depot formulations
#144Applied artificial intelligence technology for hormone therapy treatment
#145Anti-retroviral treatment using growth hormone
#146System for the transdermal delivery of active ingredient
#147Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#148METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#149Magnetic separation device and method of use
#150Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#151TREATMENT OF ADULT GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES
#152Factor IX gene therapy
#153Compositions and methods for oral delivery of therapeutic cargo
#154Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#155TREATMENT OF HORMONAL DISORDERS OF GROWTH
#156Cancer-killing cells
#157Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
#158Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin
#159Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#160METHOD TO DETECT PRE-SYMPTOM EARLY CANCER WITH ENHANCED ACCURACY
#161Musclin peptides and methods of use thereof
#162Methods and apparatus to separate biological entities
#163Microfluidic device and method of use
#164Short duration depot formulations
#165Delivery of therapeutic agents by a collagen binding protein
#166Gene vaccine for preventing and treating severe fever with thrombocytopenia syndrome
#167PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
#168METHOD FOR MANUFACTURING FEED CONTAINING SALMON GROWTH HORMONE, FEED CONTAINING SALMON GROWTH HORMONE, AND LIQUID CONTAINING SALMON GROWTH HORMONE
#169Long-Acting Therapeutic Fusion Proteins
#170COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
#171Biodegradable Drug Delivery Composition
#172Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#173PEGylated recombinant human growth hormone compounds
#174Postpartum cells derived from placental tissue, and methods of making and using the same
#175Short duration depot formulations
#176Swallowable drug delivery device and methods of drug delivery
#177Swallowable drug delivery device and methods of drug delivery
#178Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#179Multi-factor hair growth formulation
#180Injectable composition for delivery of a biologically active agent
#181Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#182Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#183Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#184SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#185Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#186Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#187Pegylated growth hormone antagonists
#188Use of growth hormone fragments
#189Oral octreotide administered in combination with other therapeutic agents
#190Anti-IL-12 Antibodies, Epitopes, Compositions, Methods and Uses
#191METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION
#192Activated polyoxazolines and conjugates and compositions comprising the same
#193Factor IX gene therapy
#194Radiation - Sterilized Biodegradable Drug Delivery Compositions
#195Swallowable drug delivery device and method of delivery
#196Amniotic fluid composition and method of using
#197Methods for treatment of surgery associated pain
#198PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#199Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
#200Polymer derivatives having particular atom arrangements
#201ELP fusion proteins for controlled and sustained release
#202Serum albumin-20K growth hormone fusion protein
#203SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES
#204LIQUID FORMULATION OF HIGHLY CONCENTRATED LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE
#205DELIVERY OF LARGE MOLECULAR WEIGHT BIOLOGICALLY ACTIVE SUBSTANCES
#206Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
#207Soft tissue repair and regeneration using postpartum-derived cells and cell products
#208Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
#209LIPID DEPOT FORMULATIONS
#210Protein conjugates
#211Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
#212Stable aqueous formulation for growth hormone
#213MRNA for use in treatment of human genetic diseases
#214PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY
#215Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#216MUSCLIN PEPTIDES AND METHODS OF USE THEREOF
#217ANTI-RETROVIRAL TREATMENT USING GROWTH HORMONE
#218Composition and method for improving sensorineural hearing
#219MICRONEEDLE ARRAY
#220MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT
#221Dry growth hormone composition transiently linked to a polymer carrier
#222Transdermal therapeutic system for the administration of peptides
#223Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#224Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#225Anti-IL-12 Antibodies, Epitopes, Compositions, Methods and Uses
#226USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING
#227Iron garnet nanoparticles for cancer radiotherapy and chemotherapy
#228Microbe transformant for weight loss and lipid reduction, the method for constructing the transformant, and application thereof
#229TREATMENT WITH HUMAN GROWTH HORMONE ANALOGUES
#230Transgenic microalgae and use thereof for oral delivery of proteins
#231METHODS AND COMPOSITIONS FOR TREATMENT OF PENILE DEFECTS
#232Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
#233Device, system and methods for the oral delivery of therapeutic compounds
#234METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES
#235METHODS AND MEANS FOR DETERMINING TREATMENT OF SUBJECTS WITH EXOGENOUS SOMATOTROPIN
#236Polymeric hGH prodrugs
#237SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES
#238Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
#239STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES
#240Long-acting growth hormone treatment
#241Treatment of hormonal disorders of growth
#242HALOGENATED INSULIN ANALOGUES OF ENHANCED BIOLOGICAL POTENCY
#243PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS
#244MICRONEEDLE ARRAY
#245Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#246Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#247Postpartum cells derived from placental tissue, and methods of making and using the same
#248Nanoparticles and methods of use
#249Delivery of therapeutic agents by a collagen binding protein
#250Stabilization of Aqueous Compositions of Proteins With Displacement Buffers
#251RADIATION-STERILIZED BIODEGRADABLE DRUG DELIVERY COMPOSITIONS
#252Biodegradable Drug Delivery Composition
#253PHOSPHOLIPID DEPOT
#254Compositions for providing agents that degrade in water
#255Activated polyoxazolines and conjugates and compositions comprising the same
#256Postpartum cells derived from placental tissue, and methods of making and using the same
#257Postpartum cells derived from placental tissue, and methods of making and using the same
#258Method of treating lupus by administering an anti-IL-12 antibody
#259Methods for treating pain caused by inflammation induced mechanical and/or thermal hypersensitivity
#260Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#261FORMULATION FOR HGH AND RHIGF-1 COMBINATION
#262Soft tissue repair and regeneration using postpartum-derived cells and cell products
#263Salts of potassium ATP channel openers and uses thereof
#264Matrix Stabilized Liposomes
#265STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES
#266Transdermal absorption sheet, and manufacturing method for the same
#267PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#268COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER
#269Short duration depot formulations
#270DELIVERY OF LARGE MOLECULAR WEIGHT BIOLOGICALLY ACTIVE SUBSTANCES
#271Dry growth hormone composition transiently linked to a polymer carrier
#272Swallowable drug delivery device and methods of drug delivery
#273Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
#274PEGYLATED GROWTH HORMONE ANTAGONISTS
#275Sialic acid derivatives for protein derivatisation and conjugation
#276Transdermal System for Sustained Delivery of Polypeptides
#277TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES
#278Amine pegylation methods for the preparation of site-specific protein conjugates
#279Method of drug formulation
#280Reversible pegylated drugs
#281Method for preparing a polymeric reagent
#282Nucleic acids encoding anti-IL-12 antibody
#283Long-acting polypeptides and methods of producing and administering same
#284System for the transdermal delivery of active ingredient
#285Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
#286COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS
#287Affinity Hydrogels for Controlled Protein Release
#288Anti-TNF antibodies, compositions, methods and uses
#289Method for improving blood persistence of protein
#290PROCESSES FOR PREPARING A SOLID POLYMER MATRIX CONTAINING A CORE MATERIAL BY PRESSURE CYCLING OF SUPERCRITICAL FLUID
#291Liquid formulation of long-acting human growth hormone immunoglobulin conjugate
#292PEGylated Recombinant Human Growth Hormone Compounds
#293Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#294ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
#295Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#296TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES
#297Pharmaceutical compositions and related methods of delivery
#298PROTEINS AND PROTEIN CONJUGATES WITH INCREASED HYDROPHOBICITY
#299Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
#300Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents